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Extracellular ATP Increases Glucose
Metabolism in Skeletal Muscle Cells
in a P2 Receptor Dependent Manner
but Does Not Contribute to
Palmitate-Induced Insulin Resistance
Ana Miguel Cruz and Craig Beall*
Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, United Kingdom
Saturated fatty acids such as palmitate contribute to the development of Type
2 Diabetes by reducing insulin sensitivity, increasing inflammation and potentially
contributing to anabolic resistance. We hypothesized that palmitate-induced ATP
release from skeletal muscle cells may increase inflammatory cytokine production and
contribute to insulin/anabolic resistance in an autocrine/paracrine manner. In C2C12
myotubes differentiated at physiological glucose concentrations (5.5 mM), palmitate
treatment (16 h) at concentrations greater than 250 µM increased release of ATP
and inflammatory cytokines IL-6 and MIF, significantly blunted insulin and amino acid-
induced signaling and reduced mitochondrial function. In contrast to our hypothesis,
degradation of extracellular ATP using apyrase, did not alter palmitate-induced insulin
resistance nor alter release of cytokines. Moreover, treatment with ATPγS (16 h), a non-
hydrolysable ATP analog, in the absence of palmitate, did not diminish insulin sensitivity.
Acute treatment with ATPγS produced insulin mimetic roles; increased phosphorylation
of PKB (aka AKT), S6K1 and ERK and enhanced GLUT4-mediated glucose uptake in
the absence of exogenous insulin. The increases in PKB and S6K1 phosphorylation
were completely prevented by pre-incubation with broad spectrum purinergic receptor
(P2R) blockers PPADs and suramin but not by P2 × 4 or P2 × 7 blockers 5-BDBD or
A-438079, respectively. Moreover, ATPγS increased IL-6 yet decreased MIF release,
similar to the cytokine profile produced by exercise. Acute and chronic treatment
with ATPγS increased glycolytic rate in a manner that was differentially inhibited by
PPADs and suramin, suggesting heterogeneous P2R activation in the control of cellular
metabolism. In summary, our data suggest that the palmitate-induced increase in ATP
does not contribute to insulin/anabolic resistance in a cell autonomous manner.
Keywords: ATP, skeletal muscle, insulin sensitivity, palmitate, IL-6, MIF, mitochondrial function
INTRODUCTION
Lipid overflow, particularly of saturated free fatty acids, contributes to the pathophysiology
of Type 2 Diabetes (T2D) by reducing insulin sensitivity and enhancing inflammation and
mitochondrial dysfunction (Wu and Ballantyne, 2017; Petersen and Shulman, 2018; Sergi et al.,
2019). These impairments are predominant in skeletal muscle, resulting in loss of glucose clearance
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that accounts for 85–90% of the impairments in glucose
homeostasis observed in T2D (Katz et al., 1983; Pendergrass et al.,
2007). Lipid-induced muscle insulin resistance (IR) is brought
about primarily by impaired insulin signaling due to build-up of
lipotoxic species and due to increased levels of circulating pro-
inflammatory cytokines. Lipotoxic moieties associated with the
development of IR include ceramides (Summers, 2006), long-
chain fatty acyl-coenzyme A (Ellis et al., 2000), diacylglycerol
(Itani et al., 2002) and acylcarnitines (Aguer et al., 2015),
among others [recently reviewed by Bergman and Goodpaster
(2020)]. Excess lipid availability also appears to negatively
regulate anabolic sensitivity, demonstrated by anabolic resistance
in overweight and obese individuals (Guillet et al., 2009; Murton
et al., 2015; Beals et al., 2016); in humans following a continuous
intralipid infusion (Stephens et al., 2015), in diet-induced obese
rodents (Anderson et al., 2008; Masgrau et al., 2012) and in high-
fat fed men in a model of disuse-induced IR (Wall et al., 2020).
A proportion of skeletal muscle inflammation occurs due to
immune cell infiltration of muscle adipose depots (Khan et al.,
2015). Independently from this, treatment with saturated fatty
acids, particularly palmitate, as the major dietary fatty acid in
blood, enhances the release of cytokines such as interleukin
6 (IL-6) and activates the IKK/NF-κB signaling cascade (Jove
et al., 2005), which is associated with the development of
skeletal muscle IR. IL-6 has been extensively characterized for its
paradoxical roles in inflammation. Acute and transient exercise-
induced increases in IL-6 contribute to the regulation of glucose
homeostasis, for example, by stimulating glucose production
(Fischer, 2006; Pedersen and Febbraio, 2008; Wolsk et al., 2010;
Eckardt et al., 2014), glucagon secretion (Barnes et al., 2014)
and altering adipose tissue function (Brandt et al., 2012). In
contrast, chronically elevated circulating IL-6 features in pro-
inflammatory conditions and is associated with muscle wasting
and IR (Kern et al., 2001; Pradhan et al., 2001). Other cytokines
and myokines, such as macrophage migration inhibitory factor
(MIF), are elevated in inflammatory conditions such as obesity
(Dandona et al., 2004) and T2D (Yabunaka et al., 2000) and
have modulatory roles in glucose homeostasis (Atsumi et al.,
2007; Miyatake et al., 2014). It remains important to establish
the autocrine and paracrine roles of these myokines in skeletal
muscle IR and inflammation.
Palmitate can also enhance muscle ATP release in a pannexin
hemi-channel-mediated manner (Pillon et al., 2014). Palmitate-
induced extracellular ATP (eATP) acts as a chemoattractant
for immune cells, suggesting that the nucleotide plays an
important role in the immune cell infiltration seen in conditions
characterized by chronic low-grade inflammation, such as obesity
and T2D (Wu and Ballantyne, 2017). In other tissues, eATP (and
degradation products) has been implicated in inflammation and
IR, as seen in adipose tissue (Tozzi and Novak, 2017; Wu and
Ballantyne, 2017); in blockade of insulin receptor signaling in
hepatocytes by adenosine diphosphate (ADP) (Chatterjee and
Sparks, 2012) and by impaired glucose clearance and hepatic
insulin sensitivity in mice lacking the ectonucleotidase CD39
(Enjyoji et al., 2008).
ATP is released from skeletal muscle in response to electrical
stimulation (Buvinic et al., 2009; Bustamante et al., 2014)
and by contraction/exercise (Steensberg et al., 2000; Osorio-
Fuentealba et al., 2013). eATP acts in an autocrine/paracrine
manner by signaling via metabotropic P2Y and ionotropic P2X
purinergic receptors (P2Rs) leading to increased intracellular
calcium concentration ([Ca2+]i) (Cseri et al., 2002; Abdul-
Ghani et al., 2008; Ito et al., 2018) and transactivation and
transinhibition of pathways such as MAPK/ERK and protein
kinase C signaling cascades (Ito et al., 2018). eATP also acts
as an important vasodilator (Mortensen et al., 2009) and likely
contributes to muscle hypertrophy following exercise (Ito et al.,
2018). Given the well-characterized pro-inflammatory roles of
eATP in other tissues and enhanced ATP release following
treatment with saturated fatty acids, we hypothesized that
palmitate-induced increases in eATP may contribute to the
development of insulin/anabolic resistance and inflammation in
an autocrine/paracrine manner in skeletal muscle, in the absence
of immune cells.
MATERIALS AND METHODS
Chemicals
Novo Nordisk Actrapid recombinant human insulin was
used for cell treatments (Henry Schein, United Kingdom).
ATPγS, PPADs, suramin, 5-BDBD, A-438079 were purchased
from Tocris (Bristol, United Kingdom). Fluo-4 Direct and
50 x MEM amino acid solution were from Thermo Fisher
Scientific (Loughborough, United Kingdom). ATP (adenosine
5’-triphosphate magnesium salt), apyrase, fatty acid-free BSA,
palmitic acid and indinavir were purchased from Sigma Aldrich
(Poole, United Kingdom).
Cell Culture
The C2C12 (ATCC CRL-1772, Mus musculus) murine myoblast
cell line was kindly gifted by colleagues at the University
of Dundee. Cell were maintained in growth medium below
70% confluence, incubated at 37◦C in humidified 5% CO2
incubators. Cells were differentiated at physiologically relevant
glucose concentrations (5.5 mM). For differentiation, cells were
plated in plating medium and incubated for 48 h (reaching
100% confluence) before medium was changed to differentiation
medium. Differentiation medium was changed every day for
6 consecutive days to replenish glucose. Experiments were
conducted after 7 days of differentiation. Refer to Supplementary
Methods for media composition and seeding densities.
Immunoblotting
Experiments in 60 mm dishes were terminated by media
collection (for ATP and cytokine analysis) and cell lysis for
protein extraction. Protein concentrations were determined
by the Bradford method and lysates subjected to SDS-
PAGE and electrotransferred to nitrocellulose membranes.
Total and phosphorylated proteins and loading controls were
immunoblotted and semi-quantified by infrared fluorescence
using the Licor Odyssey scanner. See Supplementary Methods
for lysis buffer and antibody details.
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Cytotoxicity Assessment
Cell viability was assessed in C2C12 myotubes using extracellular
lactate dehydrogenase (LDH) activity measured using a
commercially available kit and according to manufacturer’s
instructions (LDH assay kit, Abcam, United Kingdom). Briefly,
C2C12 myoblasts were differentiated as above for 6 days and
treated with palmitate (0–750 µM) or BSA controls for 16 h
before LDH activity was measured. Medium collected after
overnight treatment was centrifuged (600 × g for 10 min) and
supernatants incubated with WST and lactate dehydrogenase.
LDH oxidizes lactate (producing NADH) which reacts with WST
to generate a yellow color which was detected by absorbance
(OD450nm) using Pherastar FS plate reader.
ATP Quantification
The extracellular concentration of ATP was measured using
a commercially available assay kit and used according to
manufacturer’s instructions (ATPLite, PerkinElmer) and as
previously described (Vlachaki Walker et al., 2017). See
Supplementary Methods for details.
Assessment of Cellular Metabolism
Mitochondrial and glycolysis stress tests were performed
according to manufacturer’s instructions with minor
modifications (Agilent, United Kingdom). Briefly, for
mitochondrial stress tests, cells were treated for 16 h with
palmitate or BSA controls and treated acutely with with
oligomycin (2 µM), FCCP (1 µM) and rotenone/antimycin A
(1:1 ratio, final concentration 1 µM). For glycolysis stress tests,
cells were treated with ATPγS (up to 16 h) and treated acutely
with glucose (10 mM); oligomycin (2 µM) and 2-deoxyglucose
(2-DG, 50 mM). Refer to Supplementary Methods for details.
Cytokine Quantification
The levels of extracellular cytokines present in conditioned
media from treated cells were quantified using enzyme
linked immunosorbent assays (ELISAs). MIF and IL-6 were
measured using mouse Duo-set ELISA kits (Bio-Techne,
Abingdon, United Kingdom), performed according to
manufacturer’s instructions.
Measurement of Intracellular Calcium
Changes in intracellular calcium were assessed using the
fluorescent calcium indicator Fluo-4 Direct as previously
described (Ito et al., 2018), with minor modifications for
the C2C12 cells. Briefly, C2C12 myotubes were differentiated
in clear, flat bottomed 96 well plates. After 7 days, cells
were incubated with Fluo-4 Direct-containing phenol red free
medium for 60 min and relative changes in fluorescence
measured using a Pherastar FS plate reader. See Supplementary
Methods for details.
Measurement of Glucose Uptake
Briefly, C2C12 myotubes were differentiated in 96-well plates
for 7 days (as above). For palmitate experiments, cells were
treated for 16 h with palmitate (500 µM) or BSA control
on day 6. On day 7, cells were serum starved for 2 h and
glucose starved for 1–2 h before incubation with treatments
and subsequent incubation with 2-DG (100 µM, 15 min). 2-
DG uptake into C2C12 myotubes was assessed using the Glucose
Uptake-Glo assay (Promega, Southampton, United Kingdom).
See Supplementary Methods for details.
Statistical Analyses
In Western blotting experiments, a One−sample t−test was used
to determine significant changes in phosphorylation or total
protein expression, relative to control (normalized to 1). For
multiple group comparisons, a one−way or two-way analysis
of variance with post hoc Bonferroni were used. Statistical tests
were performed using GRAPHPAD PRISM software (Prism 7;
GraphPad Software, La Jolla, CA, United States). Results are
expressed as mean ± standard error. P values < 0.05 were taken
to indicate statistical significance.
RESULTS
Palmitate Treatment Diminishes Insulin
Sensitivity and Increases ATP Release
Differentiation of myoblasts into myotubes at physiologically
relevant glucose concentrations yielded myotubes that were
sensitive to insulin (10–100 nmol/L), as measured by significant
increases in PKB and S6K1 phosphorylation (Figures 1A,B).
In addition, treatment with mixed essential amino acids
(AA) enhanced S6K1 phosphorylation (Figure 1C). In the
absence of palmitate, insulin and AAs significantly increased
the levels of phosphorylated PKB and S6K1, however, in
the presence of 500 µM palmitate, insulin/AA-induced
PKB and S6K1 phosphorylation was significantly attenuated
(Figures 1Di–iii). We observed no change in extracellular
ATP (eATP) levels with 250 µM palmitate, but at 500 µM
palmitate, eATP levels were elevated approximately two-fold
(Figure 1E). Treatment with 500 µM palmitate did not alter
cell viability (Figure 1F). As expected, palmitate treatment
led to significant impairments in mitochondrial function with
cells displaying reduced basal oxygen consumption rates (OCR;
Figures 1Gi,ii), reduced oligomycin-sensitive OCR (a measure of
ATP production; Figures 1Gi,iii), diminished spare respiratory
capacity (Figures 1Gi,iv), increased proton leak (Figures 1G,Gv)
and reduced coupling efficiency (Figure 1Gvi).
Degradation of eATP Does Not Alter
Palmitate-Induced Insulin Resistance
and Cytokine Release
In separate studies, we confirmed that palmitate, at pro-
inflammatory concentrations, enhanced eATP and that apyrase
degraded palmitate-induced eATP by 90% (Figure 2A).
Palmitate treatment significantly blunted insulin and AA-
mediated phosphorylation of PKB and S6K1, however, apyrase
treatment did not alter blunting of insulin/AA-mediated
signaling (Figures 2Bi–iv). Palmitate significantly increased
ERK1/2 phosphorylation and this was not altered by apyrase,
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FIGURE 1 | Palmitate induces insulin resistance, enhances extracellular ATP and impairs mitochondrial function in C2C12 myotubes. Representative immunoblots for
PKB (pS473) normalized to PKB (A) and p70-S6K1 (pT389) normalized to p70-S6K1 (B) with densitometric analysis below for cells treated with insulin (0–100 nM)
for 60 min (n = 4–7). Actin and GAPDH used as loading controls. (C) Representative immunoblot for p70-S6K1 (pT389) normalized to p70-S6K1 for cells treated for
60 min with amino acids (AA, 3.34 mM) or combined with insulin (0–50 nM) (n = 3). (Di) Representative immunoblots for PKB (pS473) and p70-S6K1 (pT389)
normalized to actin with densitometric analysis in (Dii,iii), respectively, represented as fold change from respective control, for cells treated with palmitate (0–500 µM;
16 h) and insulin (20 nM) and amino acids (AA, 3.34 mM) for 60 min (n = 5–6). (E) Extracellular ATP measured by luminescence after palmitate treatment (0–500 µM;
16 h; n = 7). (F) Cytotoxicity assessed by extracellular lactate dehydrogenase in palmitate (0–500 µM; 16 h) treated myotubes (n = 3). (Gi) Representative
extracellular flux assay demonstrating oxygen consumption rate (OCR; pmoles/min/µg) at baseline and after acute injection of oligomycin (2 µM), FCCP (1 µM) and
rotenone/antimycin A (R/A; 1:1 ratio; 1 µM) at the indicated stages (n = 26–28). (Gii) Mean basal OCR before oligomycin. (Giii) Oligomycin-sensitive OCR measured
as effect of oligomycin. (Giv) Spare respiratory capacity, measured as FCCP effect. (Gv) Proton leak measured as R/A effect. (Gvi) Coupling efficiency measured as
the ratio between oligomycin-sensitive OCR and mitochondrial basal OCR expressed as percentage. *P < 0.05, **P < 0.01, ***P < 0.001 against untreated control.
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FIGURE 2 | Palmitate-induced insulin and anabolic resistance and cytokine release is not altered by hydrolysis of extracellular ATP with apyrase in C2C12 myotubes.
(A) Palmitate-induced extracellular ATP (500 µM; 16 h) hydrolysed by treatment with apyrase (0.5 units/mL; 16 h) in cells treated for 15 h with PA + apyrase and 1 h
with insulin (20 nM) and amino acids (3.34 mM) (n = 6). (Bi) Representative immunoblots for PKB (pS473), total PKB, p70-S6K1 (pT389), p70-S6K1, ERK 1/2
(pThr202/Tyr204) and actin (n = 6) for cells treated as in A. Densitometric analysis for PKB (pS473) normalized to PKB (Bii) p70-S6K1 (pT389) normalized to
p70-S6K1 (Biii) and ERK 1/2 (pThr202/Tyr204) normalized to actin (Biv). (C,D) Hydrolysis of extracellular ATP with apyrase (0.5 units/mL; 16 h) did not alter the
palmitate (500 µM; 16 h)-induced increase in release of cytokines IL-6 (C; n = 6) or MIF (D; n = 5). *P < 0.05, ***P < 0.001 for palmitate against control and ns = not
significant for the effect of apyrase on palmitate response. $$$P < 0.001 against palmitate treated group.
suggesting that additional mechanisms contribute to the
palmitate-induced phosphorylation of ERK1/2 (Figures 2Bi, iv).
We noted a modest increase in IL-6 and a significant increase
in macrophage migration inhibitory factor (MIF) induced by
palmitate but this was not significantly modified by apyrase
(Figures 2C,D). Taken together these data indicate that eATP
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does not contribute to palmitate-induced insulin resistance nor
does it significantly contribute to palmitate-induced cytokine
release from skeletal muscle.
ATPγS Treatment in the Absence of
Palmitate Does Not Alter Insulin
Sensitivity but Does Alter Cytokine
Secretion
To confirm ATP-induced signaling in C2C12 myotubes,
intracellular calcium responses were monitored following ATP
treatment. ATP caused a concentration-dependent increase
in intracellular calcium, indicating P2R-mediated signaling
(Figures 3A,B). To determine whether enhanced P2R-mediated
signaling could alter insulin sensitivity, in the absence of
palmitate, myotubes were incubated with a non-maximal
concentration of ATPγS (based on changes to intracellular
calcium levels), a non-hydrolysable ATP analog, for 16 h prior
to acute insulin treatment. As expected, acute insulin treatment
increased PKB and S6K1 phosphorylation but this was not
modified by ATPγS pre-treatment (Figures 3C,D). Interestingly,
when measuring release of IL-6 and MIF from C2C12 cells
treated with ATPγS, we observed a significant concentration-
dependent increase in IL-6 release (Figure 3E). In contrast to the
palmitate response, however, we observed a significant reduction
in MIF release following ATPγS treatment (Figure 3F).
Acute ATPγS Treatment Increases PKB
and S6K1 Phosphorylation in a
P2R-Dependent Manner and Enhances
GLUT4-Mediated Glucose Uptake in
Healthy but Not Palmitate-Challenged
Cells
To examine ATPγS signaling in more detail, C2C12 myotubes
were treated acutely with ATPγS and PKB and S6K1
FIGURE 3 | Treatment with exogenous ATP increases intracellular calcium and alters cytokine release without impairing anabolic sensitivity in C2C12 myotubes.
(A) Cells loaded with Fluo 4 direct for 60 min. Concentration-dependent increase in intracellular calcium assessed by change in fluorescence (RFU) with ATP
(0–200 µM; 30 s) with area under the curve in (B) (n = 6). (C) Representative immunoblot and densitometric analysis for PKB (pS473) normalized to PKB following
16 h treatment with 50–100 µM ATPγS and 1 h treatment with insulin (20 nM) or control (n = 6). (D) Representative immunoblot and densitometric analysis for
p70-S6K1 (pT389) normalized to p70-S6K1 following 16 h ATPγS treatment and 1 h treatment with mixed essential amino acids (AA, 3.34 mM) or control (n = 6).
(E,F) Exogenous ATPγS (50–100 µM; 16 h) enhanced IL-6 release (E; n = 6) and suppressed MIF release (F; n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 against
vehicle control.
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phosphorylation was examined. Correlating with recent
studies (Osorio-Fuentealba et al., 2013; Ito et al., 2018), we
observed significant increases in phosphorylation of both PKB
and S6K1 following ATPγS treatment (Figures 4A,B). To
determine which P2Rs may be responsible, myotubes were
pre-incubated with broad-spectrum P2R blockers PPADs
and suramin, in addition to P2 × 4 and P2 × 7 antagonists,
5-BDBD and A-438079. Interestingly, PPADs significantly
blocked ATPγS-induced increases in PKB, S6K1 and ERK1/2
phosphorylation while suramin significantly attenuated the
latter two and modestly but not significantly attenuated PKB
phosphorylation. Moreover, basal phosphorylation was also
reduced, indicating tonic receptor activation (Figures 4Ci–iv).
Acute treatment with ATPγS enhanced glucose uptake in a
concentration dependent manner, independently of insulin
(Figure 4D). In addition, pre-treatment with GLUT4 inhibitor
FIGURE 4 | ATPγS has insulin-mimetic roles in C2C12 myotubes activating PI3K/PKB and mTOR pathway signaling proteins in a P2-receptor-dependent manner
and enhancing GLUT4-mediated glucose uptake. (A,B) Representative immunoblots for PKB (pS473) normalized to PKB (A; n = 5) and p70-S6K1 (pT389)
normalized to p70-S6K1 (B; n = 6) with densitometric analysis below for cells treated with ATPγS (50–100 µM; 15 min). (Ci) Representative immunoblots for PKB
(pS473), PKB, p70-S6K1 (pT389), p70-S6K1, ERK 1/2 (pT202/TY204) and actin for cells treated with ATPγS (50 µM; 15 min) with and without broad spectrum P2
receptor antagonists PPADs (100 µM) and suramin (100 µM), P2X4R antagonist 5-BDBD (5 µM) and P2X7R antagonist A438079 (100 µM) (45 min prior to spiked
ATPγS; n = 6). Densitometric analysis for p70-S6K1 (pT389) normalized to p70-S6K1 in (Cii); PKB (pS473) normalized to PKB in (Ciii) and ERK 1/2 (pT202/TY204)
normalized to actin in (Civ). (D) Glucose uptake (2-DG; 100 µM; 15 min) assessed by luminescence following treatment with ATPγS (0–100 µM; 15 min
pre-treatment) or insulin (200 nM; 15 min pre-treatment) (n = 9). (E) Glucose uptake (2-DG; 100 µM; 15 min) following treatment with ATPγS (100 µM; 15 min) in the
presence or absence of GLUT4 inhibitor indinavir (50 µM) (n = 5). (F) Glucose uptake (2-DG; 100 µM; 15 min) following treatment with palmitate (500 µM; 16 h) and
ATPγS (100 µM; 15 min) (n = 17). *P < 0.05; **P < 0.01; ***P < 0.001 against untreated control, $$$P < 0.001 against ATPγS control.
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indinavir attenuated ATPγS-mediated glucose uptake by 40%
(Figure 4E). To assess whether ATPγS-mediated glucose uptake
was sustained in insulin resistant myotubes, we assessed glucose
uptake following palmitate treatment and demonstrated that
palmitate significantly attenuated basal and ATPγS-stimulated
glucose uptake (Figure 4F).
ATPγS Increases Glycolytic Metabolism
by a P2R-Dependent Mechanism
To examine whether the enhancement in glucose uptake led
to altered intracellular glucose metabolism, we performed a
glycolysis stress test in the presence and absence of ATPγS and
P2R antagonists. Acute injection of ATPγS induced a modest but
statistically significant increase in the extracellular acidification
rate (ECAR), in the absence of glucose (Figures 5Ai,ii). This
response was abolished by PPADs but not by suramin, indicating
this acute response is unlikely to be mediated by purely the
addition of ATPγS. In the presence of suramin, ATPγS generated
a large increase in ECAR (Figures 5Ai,ii). This was not
accompanied by increased oxygen consumption rate (OCR; data
not shown) suggesting this is not mediated by CO2 production
from the mitochondria. On addition of glucose, ATPγS treatment
augmented the ECAR response, suggesting enhanced glycolysis.
Again, this was blocked by PPADs, but not by suramin
(Figures 5Ai,iii). We next examined the effect of chronic
(16 h) ATPγS treatment on glycolytic function. Correspondingly,
ATPγS significantly enhanced glycolysis. In this paradigm,
pre-incubation with suramin prevented the enhanced ECAR
response to glucose injection by ATPγS, producing ECAR levels
similar to control (Figures 5Bi,ii). Non-glycolytic acidification
(before injection of glucose) was not altered by ATPγS pre-
treatment (Figure 5Biii).
DISCUSSION
Skeletal muscle insulin resistance contributes substantially to
the pathophysiology of T2D. Defining the pathways of insulin
resistance and uncovering potential mechanisms to improve
insulin sensitivity are key therapeutic areas requiring further
investigation. It has previously been reported that palmitate
induces release of ATP in skeletal muscle, which can recruit
immune cells (Pillon et al., 2014). In liver, saturated fatty acids
also increase hemi-channel expression to increase ATP release
which can stimulate apoptosis (Xiao et al., 2012). Moreover,
the action of ATP at P2Rs is a potent modulator of pro-
inflammatory cytokine production and release in a number
of non-immune cells including keratinocytes (Kawano et al.,
2015), endothelial cells (Seiffert et al., 2006) and astrocytes
FIGURE 5 | Treatment with ATPγS enhances extracellular acidification rate in C2C12 myotubes in a P2-receptor-dependent and insulin-independent manner. (Ai)
Representative extracellular flux assay demonstrating changes to glycolytic rate as estimated by extracellular acidification rate (ECAR) in response treatment with
ATPγS (100 pM; treatment) with or without suramin (100 pM), PPADs (100 pM) or vehicle; followed by acute injection of glucose (5.5 mM), oligomycin (2 pM) and
2DG (50 mM) at the indicated points (n = 22–24). (Aii) Acute response, ECAR prior to glucose (Aiii) Glycolysis measured as the change in ECAR following glucose
injection. (Bi) Representative extracellular flux assay for cells treated with ATPγS (100 pM; 16 h) with or without suramin (100 pM) or vehicle and acute injection of
glucose (5.5 mM), oligomycin (2 pM) and 2-DG (50 mM) at the indicated points (n = 22–24). (Bii) Glycolysis measured as the change in ECAR following glucose
injection. (Biii) Non-glycolytic acidification demonstrating mean ECAR prior to glucose injection. Data represented as mean ± SEM. *P < 0.05; **P < 0.01;
***P < 0.001 against control, $P < 0.05, $$$P < 0.001 against ATPγS.
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(Liu et al., 2000). Therefore, given the role of ATP in mediating
pro-inflammatory signaling, we postulated that ATP release
from skeletal muscle, in an autocrine/paracrine manner and
independently of immune cell recruitment, may contribute to
production of pro-inflammatory cytokines and reduced insulin
sensitivity in palmitate challenged myotubes. Here we utilized
the C2C12 myoblast cell line, differentiated into myotubes, to
observed ATP release and exogenous ATP signaling in a cell
autonomous manner. We demonstrate that palmitate induces
ATP release from skeletal muscle myotubes independently of
cell death, assessed by measurement of extracellular lactate
dehydrogenase, agreeing with previous reports demonstrating
palmitate-induced ATP release in a regulated manner (Pillon
et al., 2014). In our study, palmitate-induced ATP release
was accompanied by reduced insulin/AA sensitivity, diminished
mitochondrial function and increased release of cytokines IL-6
and MIF. Contrary to our hypothesis, degradation of eATP using
apyrase did not modify palmitate-induced insulin resistance
nor cytokine release. In contrast, enhanced eATP signaling (in
the absence of palmitate) produced insulin mimetic actions;
increasing PKB, S6K1 and ERK1/2 phosphorylation. Recently,
Ito and colleagues observed eATP-mediated increases in S6K1
and protein synthesis in C2C12 myotubes, mediated by the
P2Y2 receptor (Ito et al., 2018). Our findings are in line
with these observations and suggest that eATP has anabolic
actions in muscle.
We also observed increased GLUT4-mediated glucose
uptake into C2C12 myotubes following ATPγS treatment, in
line with previous reports (Osorio-Fuentealba et al., 2013).
Exercise significantly increases ATP demand/turnover in muscle
(Gaitanos et al., 1993) and palmitate-induced mitochondrial
dysfunction leads to reduced ATP production (Nisr and Affourtit,
2016) and, interestingly, ATP release occurs in both situations
(Osorio-Fuentealba et al., 2013; Pillon et al., 2014). Contraction
and exercise-induced ATP release contributes to glucose uptake
and cytokine release in skeletal muscle (Osorio-Fuentealba et al.,
2013; Bustamante et al., 2014). If sensitivity to ATP-induced
glucose uptake is sustained in insulin resistant states, this may
contribute to exercised-induced anabolism and provide a novel
therapeutic strategy to maintain glucose homeostasis in T2D.
We tested the acute response to ATPγS following palmitate
treatment, mimicking contraction-induced ATP release in
insulin resistant conditions, and demonstrated attenuated ATP-
simulated uptake in palmitate-challenged cells, suggesting a level
of purinergic resistance. Resistance to ATP-mediated glucose
uptake has been demonstrated at lower ATP concentrations in
muscle fibers from high-fat fed mice, but not at higher ATP
concentrations, where response is sustained {Osorio-Fuentealba
et al., 2013 #5679}. Additional experimentation is required
to investigate purinergic sensitivity in metabolically impaired
skeletal muscle. However, others have demonstrated diminished
P2R responses to ATP in insulin resistant conditions, such as
dampened P2Y2R-mediated vasodilation in T2D (Thaning et al.,
2010), indicating that purinergic resistance could also occur at
the level of glucose uptake and metabolism.
Our novel observations that ATPγS enhances skeletal muscle
cell glycolytic function suggests an important receptor-mediated
process to increase ATP generation as a positive feedback
mechanism. Similar increases in cellular metabolism have
been reported previously in endothelial cells, where exogenous
ATP increased ECAR and upregulated key glycolytic enzymes
including hexokinase, glucose transporter 1 expression and
phosphofructokinase B3 (Lapel et al., 2017). This effect of
eATP on metabolism is likely tissue specific as eATP has
been reported to decrease cellular oxygen consumption in
kidney cells, in a manner sensitive to suramin (Silva and
Garvin, 2009). It is also worth noting that PPADs and suramin
differentially blocked the effect of ATPγS on metabolism in
this study, indicating that both P2X and P2YRs may contribute
to glucose uptake and/or metabolism. Interestingly, blockade
of G-protein signaling only partially attenuated ATP-induced
glucose uptake (Osorio-Fuentealba et al., 2013), suggesting a
component of glucose transport could be P2XR mediated.
However, it is important to note that purinergic receptor and
ATPase expression can change during differentiation (Martinello
et al., 2011) and varies across species (Abdelmoez et al., 2020),
therefore determining the receptor(s) in human skeletal muscle
going forward will be important.
In our study, ATPγS also increased IL-6 and decreased MIF
release from myotubes. In general, transient and short-term
muscle-derived IL-6, such as seen during exercise, promotes
hypertrophy, myogenesis and regeneration (Fischer, 2006). IL-6
can also enhance skeletal muscle glucose uptake and fat oxidation
via AMP-activated protein kinase dependent and independent
pathways (Carey et al., 2006; Wolsk et al., 2010; Ikeda et al.,
2016). Conversely, long-term elevation of IL-6, which is evident
in inflammatory conditions, is associated with muscle wasting
and IR (Kern et al., 2001; Pradhan et al., 2001; Rui et al., 2002).
Therefore it is plausible that persistent fatty acid-induced ATP
release drives chronic IL-6 signaling to contribute to IR in an
autocrine/paracrine fashion, in addition to the recruitment of
immune cells (Pillon et al., 2014). Therefore the time course
and persistence of the ATP release likely contributes to the
differential response to acute (exercise-induced) versus chronic
(palmitate-induced) ATP release. For example, a sustained
elevation in eATP may be required to recruit and polarize
immune cells toward a pro-inflammatory phenotype (Desai
and Leitinger, 2014; Pillon et al., 2014). Furthermore, the
physiological (increased ATP demand during contraction) and
pathological context (impaired ATP production during excess
lipid) may alter the outcome of eATP signaling, which requires
further investigation.
Interestingly, ATPγS, in the absence of palmitate, decreased
MIF release. MIF is a pro-inflammatory cytokine that is packaged
into readily releasable pools (Bacher et al., 1997). The circulating
levels of MIF are elevated in T2D (Yabunaka et al., 2000), Type 1
Diabetes (Bojunga et al., 2003; Ismail et al., 2016) and a number
of other autoimmune diseases (Ayoub et al., 2008; Vincent
et al., 2019). In addition, deletion of MIF in pancreatic beta
cells protects them against palmitate-induced apoptosis (Saksida
et al., 2012). In adipose tissue, MIF can inhibit insulin-stimulated
glucose uptake (Atsumi et al., 2007) and in skeletal muscle,
MIF can reduce insulin and AICAR-mediated glucose transport
(Miyatake et al., 2014). Therefore, the significant decrease in MIF
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release following ATPγS treatment suggests a possible beneficial
effect of ATPγS.
Although not yet explored, it is also plausible that the benefits
of neuromuscular electrical stimulation (NMES) in preventing
disuse-induced atrophy during immobilization (Dirks et al.,
2014) are partly attributed to the autocrine anabolic roles of
eATP. This contraction-induced ATP release to the muscle
interstitium (Mortensen et al., 2009) is mirrored by a transient
increase in plasma ATP which increases and returns to basal
levels within 30 min of recovery (Zarêbska et al., 2018). Utilizing
ATP as a signal in this manner has a number of advantages
specifically in muscle. For example, muscle contraction causes
plasma membrane damage (McNeil and Khakee, 1992), leading
to release of intracellular contents (including ATP); differentiated
muscle cells express high levels of ATPases (Martinello et al.,
2011) that rapidly degrade eATP allowing swift termination of
the signal; and eATP can contribute to enhanced blood flow and
oxygenation into muscle (Rosenmeier et al., 2008; Mortensen
et al., 2009), which is essential during exercise. Whether this
can be exploited as a therapy remains to be determined.
Distinguishing physiological versus pharmacological actions of
ATP will be important going forward, particularly during
different states such as exercise or nutrient excess. However,
in humans, oral ATP supplementation has been reported to
increase muscle blood flow (Jäger et al., 2014) and size following
resistance training (Wilson et al., 2013). It can also promote
hypotension after exercise in hypertensive women (de Freitas
et al., 2018). The reasons for the benefits of oral ATP remain
unknown given that the bioavailability of oral ATP is very low
(Arts et al., 2012) and that direct infusion of ATP into the
femoral vein failed to increase interstitial ATP concentrations
(Mortensen et al., 2009), which suggests that oral ATP itself is
unlikely to be useful for improving glucose control. Whether
a small molecular P2R agonist, delivered systemically, could
replicate the benefits of eATP reported here will be important to
determine. A better understanding of the purinergic regulation
of glucose uptake, metabolism and cytokine release in conditions
with compromised insulin and anabolic sensitivity is required to
assess therapeutic potential of this system.
In summary, we show that extracellular ATP release does not
contribute to reduced insulin sensitivity induced by palmitate
in skeletal muscle myotubes but does increase glucose uptake
and metabolism by a P2R-dependent mechanism. Importantly,
the cytokine profile generated by ATP/ATPγS is similar to the
signature generated by moderate and high intensity exercise,
which has been shown to increases muscle and plasma ATP levels;
increase skeletal muscle glucose uptake (Carey et al., 2006; Ikeda
et al., 2016); increase circulating levels of IL-6 (Sprenger et al.,
1992) and to decrease circulating MIF levels (Wahl et al., 2014).
The potential for the exercise mimetic actions of ATP and P2R
modulation in skeletal muscle to treat conditions such as T2D
requires further study.
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